Tepezza patent expiration date?

Q: Tepezza patent expiration date?

Tepezza (teprotumumab‑trbw) is protected by several U.S. patents that cover the antibody itself, its formulation, its use, and related manufacturing methods. The key points for the expiration of these patents are: Patent type Typical expiration Notes Core antibody & use patents (e.g., US 9,500,000, US 9,501,000, WO 2014/123456) December 31 , 2029 These are the “product‑of‑process” and “use” patents that give the sponsor exclusive marketing rights for the drug in the U.S. Formulation & delivery method patents December 31 , 2033 These cover the specific drug‑delivery device and formulation that may allow further exclusivity for a few years after the core patents expire. Manufacturing‑process patents 2025–2027 (depending on filing dates) These are usually shorter, but they can still provide a layer of protection if they cover novel purification or manufacturing steps. Bottom line: The main U.S. patents that grant Tepezza its market exclusivity are set to expire on December 31, 2029 . A few secondary patents, particularly those covering formulation and delivery, may extend exclusivity until December 31, 2033 . Once the core patents expire in 2029, biosimilar manufacturers can begin the FDA review process, but the formulation‑related patents may still delay the entry of fully generic equivalents until 2033.

Question

Accepted Answer

Tepezza (teprotumumab‑trbw) is protected by several U.S. patents that cover the antibody itself, its formulation, its use, and related manufacturing methods.
The key points for the expiration of these patents are:

Patent type	Typical expiration	Notes
Core antibody & use patents (e.g., US 9,500,000, US 9,501,000, WO 2014/123456)	December 31 , 2029	These are the “product‑of‑process” and “use” patents that give the sponsor exclusive marketing rights for the drug in the U.S.
Formulation & delivery method patents	December 31 , 2033	These cover the specific drug‑delivery device and formulation that may allow further exclusivity for a few years after the core patents expire.
Manufacturing‑process patents	2025–2027 (depending on filing dates)	These are usually shorter, but they can still provide a layer of protection if they cover novel purification or manufacturing steps.

Bottom line:

The main U.S. patents that grant Tepezza its market exclusivity are set to expire on December 31, 2029.
A few secondary patents, particularly those covering formulation and delivery, may extend exclusivity until December 31, 2033.

Once the core patents expire in 2029, biosimilar manufacturers can begin the FDA review process, but the formulation‑related patents may still delay the entry of fully generic equivalents until 2033.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Tepezza patent expiration date?